Hybrid business models for ‘Organ-on-a-Chip’ technology: the best of both worlds

L.H.M. van de Burgwal, P. van Dorst, H. Viëtor, R. Luttge, E. Claassen

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Current in vitro and in vivo preclinical models often have limited predictive value for translation to the clinical setting. The emerging ‘Organ-on-a-Chip’ (OOC) technology provides a better resemblance to the human physiology through combining 3D configuration of human-derived cells with microfluidic techniques, potentially improving translation. However, due to the disruptive nature of the OOC technology, it is unclear how to best achieve a product-market fit. Data on currently employed business models was collected by 14 semi-structured interviews with representatives from OOC companies. Customer needs were collected by means of an online questionnaire among 62 (potential) end-users. Both companies and customers preferred the Hybrid business model, in which both products and services were offered. Customized services were only moderately preferred over standard services, limiting the potential for price premiums. Razor blade business models facilitate investments in laboratory equipment while locking in the purchase of disposable OOC devices. Current and future generations of in vitro technologies would benefit from combining the best of product and service business models into the Hybrid business model. Downward price pressures are expected to lead to ever-lower pricing and to facilitate more predictive, high throughput screening with a high societal impact on the longer term.

LanguageEnglish
Pages55-63
Number of pages9
JournalPharmaNutrition
Volume6
Issue number2
DOIs
StatePublished - 1 Jun 2018

Fingerprint

Technology
translation (genetics)
laboratory equipment
human physiology
Equipment and Supplies
Microfluidics
Social Responsibility
interviews
questionnaires
Interviews
screening
markets
Pressure
Costs and Cost Analysis
cells
In Vitro Techniques
methodology

Keywords

  • Business model
  • Hybrid model
  • Innovation
  • Organ-on-a-Chip
  • Preclinical

Cite this

van de Burgwal, L. H. M., van Dorst, P., Viëtor, H., Luttge, R., & Claassen, E. (2018). Hybrid business models for ‘Organ-on-a-Chip’ technology: the best of both worlds. PharmaNutrition, 6(2), 55-63. DOI: 10.1016/j.phanu.2018.02.001
van de Burgwal, L.H.M. ; van Dorst, P. ; Viëtor, H. ; Luttge, R. ; Claassen, E./ Hybrid business models for ‘Organ-on-a-Chip’ technology : the best of both worlds. In: PharmaNutrition. 2018 ; Vol. 6, No. 2. pp. 55-63
@article{a5adab1405c040e88b10a493b80fe302,
title = "Hybrid business models for ‘Organ-on-a-Chip’ technology: the best of both worlds",
abstract = "Current in vitro and in vivo preclinical models often have limited predictive value for translation to the clinical setting. The emerging ‘Organ-on-a-Chip’ (OOC) technology provides a better resemblance to the human physiology through combining 3D configuration of human-derived cells with microfluidic techniques, potentially improving translation. However, due to the disruptive nature of the OOC technology, it is unclear how to best achieve a product-market fit. Data on currently employed business models was collected by 14 semi-structured interviews with representatives from OOC companies. Customer needs were collected by means of an online questionnaire among 62 (potential) end-users. Both companies and customers preferred the Hybrid business model, in which both products and services were offered. Customized services were only moderately preferred over standard services, limiting the potential for price premiums. Razor blade business models facilitate investments in laboratory equipment while locking in the purchase of disposable OOC devices. Current and future generations of in vitro technologies would benefit from combining the best of product and service business models into the Hybrid business model. Downward price pressures are expected to lead to ever-lower pricing and to facilitate more predictive, high throughput screening with a high societal impact on the longer term.",
keywords = "Business model, Hybrid model, Innovation, Organ-on-a-Chip, Preclinical",
author = "{van de Burgwal}, L.H.M. and {van Dorst}, P. and H. Vi{\"e}tor and R. Luttge and E. Claassen",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.phanu.2018.02.001",
language = "English",
volume = "6",
pages = "55--63",
journal = "PharmaNutrition",
issn = "2213-4344",
publisher = "Elsevier",
number = "2",

}

van de Burgwal, LHM, van Dorst, P, Viëtor, H, Luttge, R & Claassen, E 2018, 'Hybrid business models for ‘Organ-on-a-Chip’ technology: the best of both worlds' PharmaNutrition, vol. 6, no. 2, pp. 55-63. DOI: 10.1016/j.phanu.2018.02.001

Hybrid business models for ‘Organ-on-a-Chip’ technology : the best of both worlds. / van de Burgwal, L.H.M.; van Dorst, P.; Viëtor, H.; Luttge, R.; Claassen, E.

In: PharmaNutrition, Vol. 6, No. 2, 01.06.2018, p. 55-63.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Hybrid business models for ‘Organ-on-a-Chip’ technology

T2 - PharmaNutrition

AU - van de Burgwal,L.H.M.

AU - van Dorst,P.

AU - Viëtor,H.

AU - Luttge,R.

AU - Claassen,E.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Current in vitro and in vivo preclinical models often have limited predictive value for translation to the clinical setting. The emerging ‘Organ-on-a-Chip’ (OOC) technology provides a better resemblance to the human physiology through combining 3D configuration of human-derived cells with microfluidic techniques, potentially improving translation. However, due to the disruptive nature of the OOC technology, it is unclear how to best achieve a product-market fit. Data on currently employed business models was collected by 14 semi-structured interviews with representatives from OOC companies. Customer needs were collected by means of an online questionnaire among 62 (potential) end-users. Both companies and customers preferred the Hybrid business model, in which both products and services were offered. Customized services were only moderately preferred over standard services, limiting the potential for price premiums. Razor blade business models facilitate investments in laboratory equipment while locking in the purchase of disposable OOC devices. Current and future generations of in vitro technologies would benefit from combining the best of product and service business models into the Hybrid business model. Downward price pressures are expected to lead to ever-lower pricing and to facilitate more predictive, high throughput screening with a high societal impact on the longer term.

AB - Current in vitro and in vivo preclinical models often have limited predictive value for translation to the clinical setting. The emerging ‘Organ-on-a-Chip’ (OOC) technology provides a better resemblance to the human physiology through combining 3D configuration of human-derived cells with microfluidic techniques, potentially improving translation. However, due to the disruptive nature of the OOC technology, it is unclear how to best achieve a product-market fit. Data on currently employed business models was collected by 14 semi-structured interviews with representatives from OOC companies. Customer needs were collected by means of an online questionnaire among 62 (potential) end-users. Both companies and customers preferred the Hybrid business model, in which both products and services were offered. Customized services were only moderately preferred over standard services, limiting the potential for price premiums. Razor blade business models facilitate investments in laboratory equipment while locking in the purchase of disposable OOC devices. Current and future generations of in vitro technologies would benefit from combining the best of product and service business models into the Hybrid business model. Downward price pressures are expected to lead to ever-lower pricing and to facilitate more predictive, high throughput screening with a high societal impact on the longer term.

KW - Business model

KW - Hybrid model

KW - Innovation

KW - Organ-on-a-Chip

KW - Preclinical

UR - http://www.scopus.com/inward/record.url?scp=85042513113&partnerID=8YFLogxK

U2 - 10.1016/j.phanu.2018.02.001

DO - 10.1016/j.phanu.2018.02.001

M3 - Article

VL - 6

SP - 55

EP - 63

JO - PharmaNutrition

JF - PharmaNutrition

SN - 2213-4344

IS - 2

ER -

van de Burgwal LHM, van Dorst P, Viëtor H, Luttge R, Claassen E. Hybrid business models for ‘Organ-on-a-Chip’ technology: the best of both worlds. PharmaNutrition. 2018 Jun 1;6(2):55-63. Available from, DOI: 10.1016/j.phanu.2018.02.001